Network origin in Klaus Mauch first degree
Entity | Entity type | Industry | |
---|---|---|---|
Insilico Biotechnology AG
Insilico Biotechnology AG Packaged SoftwareTechnology Services Part of Yokogawa Electric Corp., Insilico Biotechnology AG is a German company that develops software for biotechnology. The company is based in Stuttgart, Germany. The company was founded in 2001 by Klaus Mauch. Klaus Mauch has been the CEO since 2001. Insilico Biotechnology was acquired by Yokogawa Electric Corp. on November 02, 2021 for $30.14 million.
5
| Subsidiary | Packaged Software | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Klaus Mauch via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
PLUG POWER INC. | Electronic Production Equipment | Director/Board Member | |
GEVO, INC. | Chemicals: Specialty | Director/Board Member | |
PROMIS NEUROSCIENCES, INC. | Biotechnology | Director/Board Member | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
University of Hohenheim | College/University | Graduate Degree | |
FiveT Capital AG
FiveT Capital AG Investment ManagersFinance FiveT Capital AG (FiveT Capital) is an independent Swiss financial advisory firm which was founded by Johannes Minho Roth in 2006 which specializes in absolute return investment strategies. Formerly known as FiveT Capital Management AG, the firm aims to exploit opportunities in the European stock market, especially in Germany, by combining fundamental research and trading and execution. Based in Zurich, FiveT Capital manages the Cayman Islands-domiciled FiveMore Fund Ltd., backed primarily by high net-worth clients, funds of hedge funds and institutional investors. The firm operates their own trading and execution desk, allowing them to engage in proprietary trading and exploit market inefficiencies. | Investment Managers | Chief Executive Officer | |
Fivet Capital AG (Private Banking)
Fivet Capital AG (Private Banking) Investment ManagersFinance Fivet Capital AG (Private Banking) (Fivet Capital-PB) is the private banking division subsidiary of Fivet Capital AG, a hedge fund manager headquartered in Zurich, Switzerland. The firm was founded in 2006 and formerly known as FiveT Capital Wealth Management. Fivet Capital-PB provides wealth management and advisory services to high-net worth individuals, family offices and institutional investors. | Investment Managers | Founder | |
PHORM CORPORATION LTD | Advertising/Marketing Services | Director/Board Member | |
FiveT Capital Holding AG
FiveT Capital Holding AG Financial ConglomeratesFinance FiveT Capital Holding AG provides investment related services. The private company is based in Pfäffikon, Switzerland. The Swiss company was founded by Johannes Minho Roth. Johannes Minho Roth has been the CEO since incorporation. | Financial Conglomerates | Founder | |
FiveT Fintech
FiveT Fintech Investment ManagersFinance FiveT Fintech AG (FiveT Fintech) is a venture capital firm founded in 2018 by Francisco Fernandez Griñon and Alexander Christen. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor | |
PreComb Therapeutics AG
PreComb Therapeutics AG Pharmaceuticals: MajorHealth Technology PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then. | Pharmaceuticals: Major | Founder |
Statistics
International
Switzerland | 7 |
United States | 3 |
Germany | 3 |
Canada | 2 |
Singapore | 2 |
Sectoral
Finance | 5 |
Health Technology | 3 |
Commercial Services | 3 |
Consumer Services | 3 |
Electronic Technology | 2 |
Operational
Director/Board Member | 9 |
Founder | 4 |
Independent Dir/Board Member | 4 |
Chief Executive Officer | 3 |
Corporate Officer/Principal | 3 |
Most connected contacts
Insiders | |
---|---|
Johannes Roth | 10 |
Peter Steiner | 4 |
Bertram Layer | 1 |
Dirk Rathfelder | 1 |
Lothar Terfloth | 1 |
- Stock Market
- Insiders
- Klaus Mauch
- Company connections